Michael Scharl on the microbiome as therapeutic agent

On 3 December 2024, the NCCR Microbiomes Seminar Series is thrilled to host Michael Scharl, Chief of Service in the Department of Gastroenterology and Hepatology at the University Hospital Zurich (USZ) and Professor of translational microbiome research at the University of Zurich.

Michael Scharl’s group investigates how the human gut microbiome can help alleviate severe gastrointestinal ailments, including chronic inflammatory bowel diseases and colorectal cancer. To this end, the group seeks to improve understanding of the complex relationships between genetic predisposition, intestinal bacteria and uncontrolled immune responses.

Since 2019, Michael Scharl is Head of the Translational Microbiome Research Center at USZ. He develops translational approaches with partners in academia and industry, using molecular biology methods on human-derived cellular models, in animal studies and clinical trials. Michael Scharl is also the co-founder of Recolony, a start-up that develops biotherapeutic products against colorectal cancer, based on selected commensal bacteria.

Michael Scharl will give a talk entitled ‘The microbiome as therapeutic agent in malignant and chronic inflammatory diseases’. The seminar will take place on 3 December 2024, from 12h00 to 13h00 CET. You can access this public seminar through this Zoom link.